Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma
Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma
批准号:
nhmrc : GNT1127387
负责人:
A/Pr Jake Shortt
金额:
$49.79万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2017
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2017-01-01 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered that IMiDs destroy proteins that myeloma cells use to ‘read’ cancer-causing genes in their own DNA. We will therefore investigate how important the destruction of these ‘gene readers’ is in myeloma cells, including patient samples. This will set up future studies targeting ‘gene readers’ using IMiDs in combination with other targeted drugs in clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting and defining the immune regulatory activities of BET bromodomain inhibitors
-
批准号:nhmrc : 1123432
-
项目类别:Project Grants
-
资助金额:$61.56万
-
财政年份:2017
-
负责人:A/Pr Jake Shortt
-
依托单位:
Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma
-
批准号:nhmrc : 1127387
-
项目类别:Project Grants
-
资助金额:$33.97万
-
财政年份:2017
-
负责人:A/Pr Jake Shortt
-
依托单位:
A phase I study of the first in class dual IMiD/bromodomain inhibitor N-methyl-2-pyrrolidone (NMP) in relapsed and refractory multiple myeloma.
-
批准号:nhmrc : 1067516
-
项目类别:Project Grants
-
资助金额:$36.74万
-
财政年份:2014
-
负责人:A/Pr Jake Shortt
-
依托单位:
NMP in myeloma
-
批准号:nhmrc : GNT1067516
-
项目类别:Project Grants
-
资助金额:$53.36万
-
财政年份:2014
-
负责人:A/Pr Jake Shortt
-
依托单位:
海外基金